z-logo
open-access-imgOpen Access
Expression Quantitative Trait Loci and Receptor Pharmacology Implicate Arg1 and the GABA-A Receptor as Therapeutic Targets in Neuroblastoma
Author(s) -
Christopher S. Hackett,
David A. Quigley,
Robyn A. Wong,
Justin Chen,
Christine Cheng,
Young Song,
Jun S. Wei,
Ludmila Pawlikowska,
Yun Bao,
David Goldenberg,
Kim Nguyễn,
W. Clay Gustafson,
Sundari Rallapalli,
Yoon-Jae Cho,
James M. Cook,
С. В. Козлов,
JianHua Mao,
Terry Van Dyke,
PuiYan Kwok,
Javed Khan,
Allan Balmain,
QiWen Fan,
William A. Weiss
Publication year - 2014
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2014.09.046
Subject(s) - neuroblastoma , biology , receptor , cancer research , signal transduction , mapk/erk pathway , gabaa receptor , neuroscience , pharmacology , microbiology and biotechnology , genetics , cell culture
The development of targeted therapeutics for neuroblastoma, the third most common tumor in children, has been limited by a poor understanding of growth signaling mechanisms unique to the peripheral nerve precursors from which tumors arise. In this study, we combined genetics with gene-expression analysis in the peripheral sympathetic nervous system to implicate arginase 1 and GABA signaling in tumor formation in vivo. In human neuroblastoma cells, either blockade of ARG1 or benzodiazepine-mediated activation of GABA-A receptors induced apoptosis and inhibited mitogenic signaling through AKT and MAPK. These results suggest that ARG1 and GABA influence both neural development and neuroblastoma and that benzodiazepines in clinical use may have potential applications for neuroblastoma therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom